Metformin Indications, Dosage, Adverse Reactions, and Contraindications
Authors:
- Roxana Adriana StoicaRSRoxana Adriana Stoica
- Diana Simona ȘtefanDȘDiana Simona Ștefan
- Manfredi RizzoMRManfredi Rizzo
- Andra Iulia SuceveanuASAndra Iulia Suceveanu
- Adrian Paul SuceveanuASAdrian Paul Suceveanu
- Cristian SerafinceanuCSCristian Serafinceanu
- Anca Pantea-StoianAPAnca Pantea-Stoian
Open Access
- 27 May 2020
- book chapter
- Published by IntechOpen
Abstract
Metformin or dimethyl biguanide is the oral antidiabetic drug with the most extensive experience of prescribing in the clinical practice of type 2 diabetes mellitus. In this chapter, we reviewed the indications, contraindications, and adverse drug reactions (ADR) of metformin. The most significant adverse drug reactions of metformin are lactic acidosis, allergies, hypoglycemia, vitamin B12 deficiency, altered taste, and gastrointestinal intolerance. Metformin is contraindicated in severe chronic diseases (hepatic, renal, and cardiac failure) or acute complications of diabetes (ketoacidosis and hyperosmolar state). Metformin is considered by all international guidelines the first-line treatment in type 2 diabetes mellitus (T2DM) together with medical, nutritional therapy. It is one of the most prescribed molecules worldwide. Furthermore, metformin can also be prescribed for other diseases like polycystic ovary syndrome or prediabetes (impaired glucose tolerance/fasting hyperglycemia). Recent studies have shown positive results concerning the use of metformin for cardiovascular or neuroprotective effects; also, several scientific papers are suggesting an antitumor or antiaging effect of metformin. Having such an excellent efficiency in practice, thus predicting its sustainability on the pharmaceutical market, research is directed toward characterizing metformin action on bacteria genera in the gut. Modifying the microbiota composition by pre- and probiotics could improve metformin action.Keywords
This publication has 86 references indexed in Scilit:
- Metformin vs Insulin in the Management of Gestational Diabetes: A Meta-AnalysisPLOS ONE, 2013
- Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adultsObesity, 2013
- Metformin Inhibits Glutaminase Activity and Protects against Hepatic EncephalopathyPLOS ONE, 2012
- Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes RegisterBMJ Open, 2012
- Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic PatientsDiabetes Care, 2010
- Metformin Associated With Lower Cancer Mortality in Type 2 DiabetesDiabetes Care, 2009
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Effect of metformin on bile salt circulation and intestinal motility in Type 2 diabetes mellitusDiabetic Medicine, 1998